Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX – Get Rating) – Stock analysts at Diamond Equity issued their Q2 2022 EPS estimates for Salarius Pharmaceuticals in a research report issued to clients and investors on Wednesday, May 18th. Diamond Equity analyst H. Diamond expects that the company will earn ($0.11) per share for the quarter. Diamond Equity also issued estimates for Salarius Pharmaceuticals’ Q3 2022 earnings at ($0.11) EPS and Q4 2022 earnings at ($0.13) EPS.
Several other equities analysts also recently commented on SLRX. HC Wainwright cut their price target on shares of Salarius Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating on the stock in a report on Friday, March 11th. Zacks Investment Research upgraded shares of Salarius Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, May 5th.
Salarius Pharmaceuticals (NASDAQ:SLRX – Get Rating) last announced its earnings results on Thursday, March 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.01. During the same quarter in the previous year, the firm earned ($0.10) EPS.
A number of hedge funds have recently modified their holdings of the business. Geode Capital Management LLC grew its stake in Salarius Pharmaceuticals by 9.5% in the 4th quarter. Geode Capital Management LLC now owns 390,115 shares of the company’s stock worth $193,000 after acquiring an additional 34,001 shares in the last quarter. Renaissance Technologies LLC bought a new position in shares of Salarius Pharmaceuticals during the fourth quarter valued at approximately $89,000. Two Sigma Advisers LP bought a new position in shares of Salarius Pharmaceuticals during the third quarter valued at approximately $114,000. Millennium Management LLC boosted its stake in shares of Salarius Pharmaceuticals by 77.6% during the third quarter. Millennium Management LLC now owns 59,480 shares of the company’s stock valued at $61,000 after purchasing an additional 25,992 shares in the last quarter. Finally, Morgan Stanley boosted its stake in shares of Salarius Pharmaceuticals by 54.8% during the third quarter. Morgan Stanley now owns 759,772 shares of the company’s stock valued at $775,000 after purchasing an additional 268,970 shares in the last quarter. Institutional investors and hedge funds own 11.38% of the company’s stock.
About Salarius Pharmaceuticals (Get Rating)
Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.
- Get a free copy of the StockNews.com research report on Salarius Pharmaceuticals (SLRX)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Will John Deere’s Earnings Help to Calm the Markets?
- Lowe’s Companies Has Not Bottomed
Receive News & Ratings for Salarius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Salarius Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.